Financial reports
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
9 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K/A
2021 FY
Annual report (amended)
25 Mar 22
10-K
2021 FY
Annual report
24 Feb 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Completion of Acquisition or Disposition of Assets
27 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
26 Dec 23
8-K
Other Events
15 Dec 23
8-K
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Other Events
25 Oct 23
8-K
Regulation FD Disclosure
27 Sep 23
8-K
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
21 Sep 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Aug 23
8-K
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
14 Aug 23
8-K
Departure of Directors or Certain Officers
24 Jul 23
Registration and prospectus
15-12G
Securities registration termination
9 Jan 24
POSASR
Automatic shelf registration (post-effective amendment)
2 Jan 24
POS AM
Prospectus update (post-effective amendment)
2 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jan 24
S-8 POS
Registration of securities for employees (post-effective amendment)
2 Jan 24
25-NSE
Exchange delisting
28 Dec 23
425
Business combination disclosure
27 Sep 23
425
Business combination disclosure
21 Sep 23
424B5
Prospectus supplement for primary offering
28 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
15 Dec 23
DEFM14A
Proxy related to merger
21 Nov 23
DEFA14A
Additional proxy soliciting materials
8 Jun 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
DEFA14A
Additional proxy soliciting materials
12 Apr 22
DEF 14A
Definitive proxy
12 Apr 22
DEFA14A
Additional proxy soliciting materials
7 Apr 21
DEF 14A
Definitive proxy
7 Apr 21
Other
EFFECT
Notice of effectiveness
3 Jan 24
EFFECT
Notice of effectiveness
28 Mar 22
CORRESP
Correspondence with SEC
25 Mar 22
UPLOAD
Letter from SEC
15 Mar 22
EFFECT
Notice of effectiveness
1 Apr 21
CORRESP
Correspondence with SEC
29 Mar 21
CORRESP
Correspondence with SEC
29 Mar 21
UPLOAD
Letter from SEC
24 Mar 21
EFFECT
Notice of effectiveness
5 Jun 20
CERT
Certification of approval for exchange listing
2 Jun 20
Ownership
SC 13G/A
Founders Fund V Management, LLC
14 Feb 24
SC 13D/A
EPIQ Capital Group, LLC
5 Jan 24
4
Chad Boeding
29 Dec 23
4
Aaron VanDevender
28 Dec 23
4
John W Smither
28 Dec 23
4
Holly Caren Schachner
28 Dec 23
4
Tahir Ph.D. Mahmood
28 Dec 23
4
Brandon Hants
28 Dec 23
4
Shawn Cross
28 Dec 23
4
Charlene A. Banard
28 Dec 23